Care facilitation advances movement along the hepatitis C Care continuum for persons with human immunodeficiency virus, hepatitis C, and substance use: A randomized clinical trial (CTN-0064).

This is the primary outcomes article for CTN-0064.

Direct-acting antivirals can cure hepatitis C virus (HCV). Persons with HCV/HIV and living with substance use are disadvantaged in benefiting from advances in HCV treatment.

In this randomized controlled trial, participants with HCV/HIV were randomized between February 2016 and January 2017 to either care facilitation or control. Twelve-month follow-up assessments were completed in January 2018.Care facilitation group participants received motivation and strengths-based case management addressing retrieval of HCV viral load results, engagement in HCV/HIV care, and medication adherence. Control group participants received referral to HCV evaluation and an offer of assistance in making care appointments. Primary outcome was number of steps achieved along a series of 8 clinical steps (eg, receiving HCV results, initiating treatment, sustained virologic response [SVR]) of the HCV/HIV care continuum over 12 months postrandomization.

Three hundred eighty-one individuals were screened and 113 randomized. Median age was 51 years; 58.4% of participants were male and 72.6% were Black/African American. Median HIV-1 viral load was 27 209 copies/mL, with 69% having a detectable viral load. Mean number of steps completed was statistically significantly higher in the intervention group vs controls (2.44 vs 1.68 steps; 2 [1] = 7.36, P = .0067). Men in the intervention group completed a statistically significantly higher number of steps than controls. Eleven participants achieved SVR with no difference by treatment group.

Conclusions: The care facilitation intervention increased progress along the HCV/HIV care continuum, as observed for men and not women. Study findings also highlight continued challenges to achieve individual-patient SVR and population-level HCV elimination.

Related protocols: CTN-0064

Categories: CTN primary outcomes, Hepatitis C, HIV/AIDS
Tags: Article (Peer-Reviewed)
Authors: Metsch, Lisa R.; Feaster, Daniel J.; Gooden, Lauren K.; Masson, Carmen L.; Perlman, David C.; Jain, Mamta K.; Matheson, Tim; Nelson, C. Mindy; Jacobs, Petra; Tross, Susan; Haynes, Louise F.; Lucas, Gregory M.; Colasanti, Jonathan A.; Rodriguez, Allan; Drainoni, Mari-Lynn; Osorio, Georgina; Nijhawan, Ank E.; Jacobson, Jeffrey M.; Sullivan, Meg; Metzger, David; Vergara-Rodriguez, Pamela; Lubelchek, Ronald; Duan, Rui; Batycki, Jacob N.; Matthews, Abigail G.; Munoz, Felipe; Jelstrom, Eve; Mandler, Raul N.; del Rio, Carlos
PMCID: PMC8339611
PMID: 34377726
Source: Open Forum Infectious Diseases 2021;8(8):ofab334. [doi: 10.1093/ofid/ofab334]